TAGS
Regimen
- Experimental
- TAS-102 (trifluridine/tipiracil) 35 mg/m2 BID d1-5/8-12 q28 + BSC
- Control
- placebo + BSC
Population
Advanced gastric/GEJ cancer progressing after >=2 prior regimens (3L+)
Key finding
mOS 5.7 vs 3.6 mo (HR 0.69, 95% CI 0.56-0.85, p=0.00058); mPFS HR 0.57
Source: PMID 30355453
Timeline
Guideline citations
- NCCN GASTRIC (p.47)
- CSCO GASTRIC 2025 (p.105)⚠️ OCR source